Glukose Sad

Glukose Sad is an intravenous (IV) solution containing glucose monohydrate as its sole active ingredient. It is supplied in a sterile liquid form for infusion, and is marketed within the European Union. The product provides a readily available source of carbohydrate for patients requiring parenteral nutrition or rapid correction of low blood glucose, and is classified as a nutrient excipient and is intended for use under medical supervision.

Glukose Sad is used in clinical settings where an immediate source of glucose is required.

- Management of acute hypoglycemia in hospitalized patients. - Component of parenteral nutrition formulations. - Support during surgical procedures to maintain blood glucose levels. - Fluid and electrolyte replacement when combined with appropriate electrolytes. - Energy source for patients unable to tolerate oral intake.

Intravenous administration of glucose monohydrate can be associated with a range of observed effects, most of which are related to the metabolic and vascular response to the solution.

Common: - Transient hyperglycemia. - Local irritation or phlebitis at the infusion site. - Mild nausea. - Electrolyte shifts such as low potassium. - Headache.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity or allergic reaction. - Hyperosmolar coma in susceptible patients. - Rapid fluid overload causing pulmonary edema.

Because Glukose Sad delivers a concentrated carbohydrate load directly into the bloodstream, several precautions should be observed before and during its use.

- Verify blood glucose level before infusion to avoid excessive rise. - Adjust infusion rate in patients with renal or cardiac insufficiency. - Use aseptic technique to prevent contamination. - Monitor electrolytes, especially potassium and sodium, during therapy. - Avoid use in patients with known hypersensitivity to glucose solutions. - Consider contraindication in uncontrolled diabetes mellitus.

Glucose solutions can interact with other medications or clinical conditions, influencing their efficacy or safety.

Avoid: - Co-administration with rapid‑acting insulin without dose adjustment. - Simultaneous infusion of high‑concentration potassium chloride. - Use with hypertonic saline solutions that may exacerbate hyperosmolar states.

Use with caution: - Concurrent use of diuretics that affect fluid balance. - Administration alongside beta‑blockers in patients prone to hypoglycemia. - Overlap with medications that affect serum potassium, such as ACE inhibitors.